1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.
Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 17, 62, 47, 6, 45, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Small-Cell Lung Cancer - Overview
- Small-Cell Lung Cancer - Therapeutics Development
- Small-Cell Lung Cancer - Therapeutics Assessment
- Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
- Small-Cell Lung Cancer - Drug Profiles
- Small-Cell Lung Cancer - Dormant Projects
- Small-Cell Lung Cancer - Discontinued Products
- Small-Cell Lung Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Small-Cell Lung Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2020
- Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
- Small-Cell Lung Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Akeso Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Alkermes Plc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Allogene Therapeutics Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Amgen Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Apollomics Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Aprea Therapeutics AB, H1 2020
- Small-Cell Lung Cancer - Pipeline by Ascenta Therapeutics Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Ascentage Pharma Group International, H1 2020
- Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Auransa Inc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Autolus Therapeutics Plc, H1 2020
- Small-Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2020
- Small-Cell Lung Cancer - Dormant Projects, H1 2020
- Small-Cell Lung Cancer - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Small-Cell Lung Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Aeglea BioTherapeutics Inc
- Akeso Inc
- Alkermes Plc
- Allogene Therapeutics Inc
- Amgen Inc
- Andarix Pharmaceuticals Inc
- Apollomics Inc
- Aprea Therapeutics AB
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Auransa Inc
- Autolus Therapeutics Plc
- Bavarian Nordic A/S
- BeiGene Ltd
- Beta Pharma Inc
- BeyondSpring Inc
- Biogenera SpA
- BioLineRx Ltd
- BioNTech SE
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cardiff Oncology Inc
- Carrick Therapeutics UK Ltd
- Celldex Therapeutics Inc
- Checkpoint Therapeutics Inc
- Chiome Bioscience Inc
- Chipscreen Biosciences Ltd
- Coherent Biopharma
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cumberland Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Dragonfly Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- EpicentRx Inc
- Esanex Inc
- F. Hoffmann-La Roche Ltd
- Fujifilm Holdings Corp
- G1 Therapeutics Inc
- Genentech Inc
- Genexine Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hangzhou DAC Biotech Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harpoon Therapeutics Inc
- Hillstream BioPharma Inc
- Horizon Therapeutics Plc
- Hutchison MediPharma Ltd
- ImmunityBio Inc
- Immunocore Ltd
- Immunomedics Inc
- ImmunSYS Inc
- Incyte Corp
- Innovent Biologics Inc
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kuur Therapeutics Ltd
- Lee's Pharmaceutical Holdings Ltd
- Lixte Biotechnology Holdings Inc
- Luye Pharma Group Ltd
- MabVax Therapeutics Holdings Inc
- Merck & Co Inc
- Merck KGaA
- Moderna Inc
- Mologen AG
- MultiVir Inc
- Mundipharma EDO GmbH
- Nanology LLC
- NewBio Therapeutics Inc
- Ningbo Wenda Pharma
- Northlake International LLC
- Novartis AG
- NOX Pharmaceuticals Inc
- OncoFusion Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Oryzon Genomics SA
- Oxford BioTherapeutics Ltd
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- Plexxikon Inc
- Plus Therapeutics Inc
- PNB Vesper Life Science Pvt Ltd
- Processa Pharmaceuticals Inc
- ProLynx LLC
- Qilu Puget Sound Biotherapeutics Corp
- RAPT Therapeutics Inc
- Recombio SL
- Rexahn Pharmaceuticals Inc
- Rgenix Inc
- SciTech Development LLC
- Seattle Genetics Inc
- SELLAS Life Sciences Group Inc
- Seneca Therapeutics Inc
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
- Sorrento Therapeutics Inc
- Sotio AS
- Starpharma Holdings Ltd
- Stcube Inc
- Syros Pharmaceuticals Inc
- Tactical Therapeutics Inc
- Taiho Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Targovax ASA
- Tarveda Therapeutics Inc
- Telomium SAS
- Tmunity Therapeutics Inc
- Trillium Therapeutics Inc
- Woomera Therapeutics Inc
- Xbrane Biopharma AB
- Xcovery Holding Co LLC
- Xencor Inc
- Y-Biologics Inc
- Y-mAbs Therapeutics Inc
- Zensun (Shanghai) Sci & Tech Co Ltd
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
